HERON THERAPEUTICS, INC. /DE/ (HRTX) — SEC Filings

Latest SEC filings for HERON THERAPEUTICS, INC. /DE/ (HRTX), explained in plain English.

Sentiment Overview: 1 bullish, 33 neutral, 3 mixed

Recent Filings (37)

• Heron Therapeutics Files 8-K: Officer Changes & Exhibits — 8-K · 2026-04-06T08:30:11-04:00 [neutral] Risk: low
  Heron Therapeutics, Inc. filed an 8-K on April 6, 2026, reporting on the departure of a director and the appointment of a new officer. The filing also includes
• Heron's Q3 Sales Up 16%, But Debt Extinguishment Drives Net Loss Spike — 10-Q · 2025-11-04T00:00:00.000Z [mixed] Risk: high
  Heron Therapeutics, Inc. reported net product sales of $38.213 million for the three months ended September 30, 2025, an increase of 16.4% from $32.810 million
• Heron Therapeutics Announces Executive & Director Compensation Changes — 8-K · 2025-10-29T00:00:00.000Z [neutral] Risk: medium
  Heron Therapeutics, Inc. announced on October 27, 2025, changes in its executive and director compensation arrangements. The filing details the election of new
• Heron Therapeutics Files 8-K on Shareholder Votes & Financials — 8-K · 2025-10-15T00:00:00.000Z [neutral] Risk: low
  Heron Therapeutics, Inc. filed an 8-K on October 15, 2025, reporting on matters submitted to a vote of security holders and financial statements. The company, f
• Heron Therapeutics Seeks Shareholder Nod for Key Stock Issuances — DEF 14A · 2025-09-19T00:00:00.000Z [mixed] Risk: medium
  Heron Therapeutics, Inc. (HRTX) is seeking stockholder approval for two proposals related to the issuance of common stock that could exceed 19.99% of its outsta
• Heron Therapeutics Files 8-K for Material Agreement — 8-K · 2025-08-28T00:00:00.000Z [neutral] Risk: medium
  Heron Therapeutics, Inc. (HRTX) filed an 8-K on August 28, 2025, reporting a material definitive agreement entered into on August 22, 2025. The filing also incl
• Heron Therapeutics Enters Material Agreement — 8-K · 2025-08-15T00:00:00.000Z [neutral] Risk: medium
  Heron Therapeutics, Inc. announced on August 13, 2025, that it entered into a material definitive agreement. The company also reported on material modifications
• Heron Therapeutics Enters Material Definitive Agreement — 8-K · 2025-08-12T00:00:00.000Z [neutral] Risk: medium
  Heron Therapeutics, Inc. (HRTX) announced on August 6, 2025, that it has entered into a material definitive agreement. The filing does not disclose the specific
• Heron Therapeutics Narrows Q2 Loss, Boosts Revenue by 11.7% — 10-Q · 2025-08-08T00:00:00.000Z [mixed] Risk: medium
  HERON THERAPEUTICS, INC. reported a net loss of $29.7 million for the three months ended June 30, 2025, a significant improvement from the net loss of $49.5 mil
• Heron Therapeutics Sets 2025 Annual Meeting Date — 8-K · 2025-06-18T00:00:00.000Z [neutral] Risk: low
  Heron Therapeutics, Inc. (HRTX) announced on June 12, 2025, that it will hold its 2025 Annual Meeting of Stockholders on July 24, 2025. The meeting will include
• Heron Therapeutics Files Q1 2025 10-Q — 10-Q · 2025-05-06T00:00:00.000Z [neutral] Risk: medium
  Heron Therapeutics, Inc. (HRTX) filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance, including sales revenue
• Heron Therapeutics Executive Compensation Details Released — DEF 14A · 2025-04-30T00:00:00.000Z [neutral] Risk: medium
  Heron Therapeutics, Inc. filed a DEF 14A on April 30, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes i
• Heron Therapeutics Announces Board and Executive Compensation Changes — 8-K · 2025-04-29T00:00:00.000Z [neutral] Risk: low
  Heron Therapeutics, Inc. announced on April 28, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company elect
• Heron Therapeutics Files 2024 10-K — 10-K · 2025-02-27T00:00:00.000Z [neutral] Risk: medium
  Heron Therapeutics, Inc. filed its 2024 10-K on February 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as AP Phar
• Heron Therapeutics Enters Material Definitive Agreement — 8-K · 2025-02-20T00:00:00.000Z [neutral] Risk: medium
  Heron Therapeutics, Inc. (HRTX) announced on February 13, 2025, that it entered into a material definitive agreement. The company, formerly known as AP Pharma I
• Heron Therapeutics Files 8-K — 8-K · 2024-12-23T00:00:00.000Z [neutral] Risk: low
  On December 23, 2024, Heron Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits
• Gilead to Acquire Heron Therapeutics for $1.2 Billion — 8-K · 2024-12-03T00:00:00.000Z [bullish] Risk: medium
  Heron Therapeutics, Inc. announced on December 3, 2024, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for $18.00 per s
• SC 13G Filing — SC 13G · 2024-11-12T00:00:00.000Z [neutral]
• Heron Therapeutics Files Q3 2024 10-Q Report — 10-Q · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  Heron Therapeutics, Inc. reported its third-quarter results for the period ending September 30, 2024. The company's financial statements and disclosures are det
• SC 13G Filing — SC 13G · 2024-11-08T00:00:00.000Z [neutral]
• Heron Therapeutics Appoints New Chief Medical Officer — 8-K · 2024-11-04T00:00:00.000Z [neutral] Risk: medium
  Heron Therapeutics, Inc. announced on November 4, 2024, the appointment of Dr. Michael R. Green as Chief Medical Officer. Dr. Green, who previously served as Se
• SC 13G Filing — SC 13G · 2024-10-24T00:00:00.000Z [neutral]
• Heron Therapeutics Files Q2 2024 10-Q — 10-Q · 2024-08-06T00:00:00.000Z [neutral] Risk: medium
  Heron Therapeutics, Inc. filed its Q2 2024 10-Q report on August 6, 2024, detailing its financial performance for the quarter ending June 30, 2024. The company'
• Heron Therapeutics Files 8-K Report — 8-K · 2024-07-02T00:00:00.000Z [neutral] Risk: low
  On July 2, 2024, Heron Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No spe
• Heron Therapeutics Announces Corporate Changes — 8-K · 2024-06-18T00:00:00.000Z [neutral] Risk: medium
  Heron Therapeutics, Inc. announced on June 13, 2024, a series of significant corporate actions. These include the election of new directors, changes in executiv
• Rubric Capital Boosts Heron Therapeutics Stake to 10.4% — SC 13D/A · 2024-05-31T00:00:00.000Z [neutral] Risk: medium
  Rubric Capital Management LP, on May 31, 2024, filed an amendment to its Schedule 13D, disclosing a beneficial ownership of 10.4% of Heron Therapeutics, Inc. co
• Heron Therapeutics Files 8-K — 8-K · 2024-05-29T00:00:00.000Z [neutral] Risk: low
  Heron Therapeutics, Inc. filed an 8-K on May 29, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain s
• Heron Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-07T00:00:00.000Z [neutral] Risk: medium
  HERON THERAPEUTICS, INC. /DE/ (HRTX) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Heron Therapeutics, Inc. filed a 10-Q report for the period en
• Heron Therapeutics Announces 2024 Annual Meeting of Stockholders on June 13, 2024 — DEF 14A · 2024-04-29T00:00:00.000Z [neutral] Risk: medium
  HERON THERAPEUTICS, INC. /DE/ (HRTX) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Heron Therapeutics will hold its 2024 Annual Meeting of S
• Heron Therapeutics Announces Board and Executive Compensation Changes — 8-K · 2024-03-21T00:00:00.000Z [neutral] Risk: low
  Heron Therapeutics, Inc. announced on March 18, 2024, changes in its board of directors and executive compensation. Specifically, Dr. David P. Ryan was appointe
• HERON THERAPEUTICS, INC. /DE/ Files 2023 Annual Report on Form 10-K — 10-K · 2024-03-12T00:00:00.000Z [neutral] Risk: medium
  HERON THERAPEUTICS, INC. /DE/ (HRTX) filed a Annual Report (10-K) with the SEC on March 12, 2024. Filed Form 10-K for the fiscal year ended December 31, 2023. C
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• Vanguard Group Amends Heron Therapeutics Stake to 9.9% — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral] Risk: low
  The Vanguard Group, a major investment firm, filed an amended Schedule 13G/A on February 13, 2024, disclosing its ownership in Heron Therapeutics Inc. As of Dec
• Franklin Resources Amends Heron Therapeutics Stake as of Dec 31, 2023 — SC 13G/A · 2024-02-06T00:00:00.000Z [neutral]
  Franklin Resources, Inc. has filed an amendment (SC 13G/A) to its Schedule 13G, indicating a change in its ownership stake in Heron Therapeutics, Inc. /DE/ as o
• Heron Therapeutics Files Routine 8-K, Confirms Nasdaq Listing — 8-K · 2024-01-24T00:00:00.000Z [neutral]
  Heron Therapeutics, Inc. (HRTX) filed an 8-K on January 24, 2024, reporting an event that occurred on January 23, 2024. This filing primarily serves to update a
• Heron Therapeutics Reports Undisclosed Material Definitive Agreement — 8-K · 2024-01-11T00:00:00.000Z [neutral]
  Heron Therapeutics, Inc. filed an 8-K on January 11, 2024, to report an "Entry into a Material Definitive Agreement" that occurred on January 5, 2024. While the